

1 **Grape Seed Extract-Soluplus Dispersion and its Antioxidant Activity**

2 **R. Rajakumari <sup>a, b</sup>, Tatiana Volova<sup>b</sup>, Oluwatobi Samuel Oluwafemi<sup>\*c, d</sup>, Rajesh Kumar<sup>e</sup>,**

3 **Sabu Thomas<sup>a, f</sup> and Nandakumar Kalarikkal<sup>\*a, g</sup>**

4 *<sup>a</sup>International and Inter-University Centre for Nanoscience and Nanotechnology, Mahatma*  
5 *Gandhi University, Kerala, 686560, India*

6 *<sup>b</sup>Siberian Federal University, 79 Svobodnyi Av., Krasnoyarsk, 660041, Russia*

7 *E-mail: volova45@mail.ru*

8 *<sup>c</sup>Department of Chemical Sciences, University of Johannesburg, South Africa*

9 *<sup>d</sup>Centre for Nanomaterials Sciences Research, University of Johannesburg, Johannesburg,*  
10 *South Africa*

11 *E-mail: oluwafemi.oluwatobi@gmail.com*

12 *<sup>e</sup>Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of*  
13 *Medical and Technical Sciences (SIMATS), Chennai, 600077, Tamilnadu, India*

14 *E-mail: ssrajeshkumar@hotmail.com, Tel: +91 96297 39263*

15 *<sup>f</sup>School of Chemical Sciences, Mahatma Gandhi University, Kerala, 686560, India.*

16 *E-mail: sabuchathukulam@yahoo.co.uk, Fax: +91-481-2731002, Tel: +91-481-2731002*

17 *<sup>g</sup>School of Pure and Applied Physics, Mahatma Gandhi University, Kerala, 686560, India.*

18 *E-mail: nkkalarikkal@mgu.ac.in, Fax: +91-481-2731669, Tel: +91-481- 2731669*

19 *\*Corresponding Authors E mail: oluwafemi.oluwatobi@gmail.com;*

20 *nkkalarikkal@mgu.ac.in*

21

22

23

24

25

26

27 **Abstract**

28 **Objective**

29 The main objective of this work was to formulate a nanodispersion containing grape seed  
30 extract and analysed its release profile, antioxidant potential of the prepared formulations.

31 **Methods**

32 The grape seed extract (GSE) containing proanthocyanidins (PC's) has been dispersed in  
33 polymer matrix soluplus (SOLU) by the freeze-drying method. The morphological analysis  
34 was carried out using atomic force microscopy (AFM), scanning electron microscopy (SEM)  
35 and Transmission electron microscopy (TEM). The *in-vitro* release of the nanodispersion  
36 formulations was evaluated by simulated intestinal fluid (SIF). The antioxidant activity of GSE  
37 and the formulation were evaluated by employing various *in-vitro* assays such as 2, 2'-azino-  
38 bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), 2, 2-diphenyl-1- picrylhydrazyl  
39 (DPPH), Ferric reducing antioxidant power (FRAP) and peroxidation inhibiting activity.

40 **Results**

41 The formulation FIII (1:5) resulted in a stable formulation with a higher loading efficiency of  
42 95.36 %, a particle size of 69.90 nm, a polydispersity index of 0.154 and a zeta potential value  
43 of -82.10 mV. The antioxidant efficiency of GSE-SOLU evaluated by DPPH was found to be  
44 96.7 %. The ABTS and FRAP model exhibited a dose-dependent scavenging activity. Linoleic  
45 model of FIII formulation and GSE exhibited a 66.14 and 86.58 % inhibition respectively at  
46 200 µg/l.

47 **Conclusions**

48 The main reason for excellent scavenging activity of the formulations can be attributed to the  
49 presence of monomeric, dimeric, oligomeric procyanidins and the phenolic group. The present  
50 work denotes that GSE constitutes a good source of PC's and will be useful in the prevention  
51 and treatment of free radical related diseases.

52

53 **Key Words:** Grape seed extract; Proanthocyanidins; Antioxidant; Soluplus; Freeze-drying;  
54 Dispersion

55

## 56 **1. Introduction**

57 Many diseases are as a result of oxidative stress on the cells due to the release of free radicals.

58 The reactive oxygen species (ROS) are superoxide anion, hydroxyl radicals, hydrogen peroxide

59 and singlet oxygen were said to be different forms of free radicals [1]. Therefore, antioxidative

60 defence system is necessary to act against the free radicals production (Fig 1). Moreover, the

61 damage on cells due to free radicals causes several chronic diseases such as cancer, arthritis,

62 atherosclerosis, wound, neurodegenerative diseases and diabetes mellitus [2, 3]. For this

63 reason, antioxidants are commonly used in the treatment and prevention of chronic diseases.

64

65 Currently, the use of natural therapeutics based on nanotechnology in healthcare is greatly

66 utilised in areas such as drug delivery, imaging, rapid diagnosis, tissue regeneration and

67 development of new therapeutics [4–7]. The preparation of the green synthesis of

68 nanodispersion is growing into a key approach in nanotechnology. Proanthocyanidins (PCs)

69 are a class of polyphenols and chemically, they are oligomeric flavonoids found in a variety of

70 plants. It is an important constituent found in varying concentrations in GSE and the antioxidant

71 activity of PCs are higher than the widely used antioxidant molecules such as ascorbic, trolox

72 and rutin. This is because of the position of the hydroxyl groups in the PCs [8, 9]. The

73 flavonoids are quickly hydrolysed in the intestine by bacteria to generate aglycones which are

74 then metabolized into phenylacetic, phenylpropionic, and phenylvaleric form of PCs. They are

75 retained in the large intestine after an oral intake and are found not to be stable which is

76 probably due to damage of the C-ring of proanthocyanidins [10, 11].

77

78 Apart from antioxidant activity, PCs shows anticancer [12], antidiabetic [13], anti-  
79 inflammatory [14] and antibacterial activities [15]. Despite the extensive range of  
80 pharmacological properties, the usage of PCs in pharmaceutical arena is very limited owing to  
81 its poor bioavailability, poor permeability and poor stability in a biological medium [16].  
82 Therefore to circumvent the problems, PCs are entrapped/adsorbed into a biodegradable  
83 polymer. Recently, SOLU is widely used as a biodegradable polymer for many therapeutically  
84 active moieties due to its amphiphilic nature, biocompatibility, low toxicity, good mechanical  
85 strength and controlled release [17]. Selection of a proper carrier is a significant step in the  
86 formulation of nano dispersions containing compounds with low permeability and high  
87 molecular weight. Soluplus has polyvinyl caprolactam (PVC) (57 % vinyl caprolactam) –  
88 polyvinyl acetate (PVA) (30 %) – polyethylene glycol (PEG) graft copolymer vinyl acetate).  
89 SOLU carrier is one of the 4<sup>th</sup> generation of dispersions proposed in enhancing the stability of  
90 the formulation [18]. It is reported that SOLU efficiently increase the absorption of the low  
91 permeable molecules when used as a drug carrier [19]. SOLU improved the dissolution of the  
92 low bioavailable molecules by electrospinning and extrusion technology [20]. It is also reported  
93 that PC molecule has been incorporated into liposomes and nanoparticles [21] but in-depth  
94 characterisations of PCs are not reported.

95

96 In this study, proanthocyanidin molecule was dispersed into SOLU by the freeze-drying  
97 method. The GSE-SOLU dispersion was characterised by atomic force microscope (AFM),  
98 scanning electron microscope (SEM) and transmission electron microscope (TEM). The  
99 antioxidant activity was carried out to enhance its application in the food and Pharmaceutical  
100 industries. PCs dispersed in the SOLU matrix showed a controlled release behaviour indicating  
101 that the PCs dispersed SOLU may improve bioavailability and stability of PCs. The addition  
102 of SOLU in GSE retards oxidative spoilage and extends the shelf life of formulation. Moreover,  
103 this study provides better insights of GSE-SOLU as an effective antioxidant compound in food

104 and Pharmaceutical industries. The higher antioxidant activity in formulations is attributed to  
105 the SOLU which is used to scavenge or drain radicals that are harmful. This property of SOLU  
106 incorporated GSE molecule paved way for dispersing various antioxidant moieties for  
107 developing better therapeutic compounds.

108

## 109 **2. Materials and Methods**

110 Polyethylene glycol-polyvinyl acetate-polyvinyl caprolactam (Soluplus) were received from  
111 BASF Corporation, Mumbai. GSE (Proanthocyanidins) from JF Naturals, China. DPPH,  
112 ABTS, Linoleic acid, potassium persulphate, potassium ferric cyanide, Aluminum chloride,  
113 Ferrozine, Ferric chloride were obtained from Sigma Chemicals (Mumbai). The solvents used  
114 in this study were of analytical grade purchased from E-Merck (Mumbai).

115

### 116 **2.1 Lyophilisation**

117 The different ratios of GSE-SOLU (1:1 (FI), 1:3 (FII), 1:5 (FIII), 1:7 (FIV)) were dissolved in  
118 water and the prepared aqueous solution was dispersed using magnetic stirrer at 125 rpm for  
119 30 min. Then, the dispersion was sonicated for about 10 mins at room temperature and it was  
120 frozen at  $-45\text{ }^{\circ}\text{C}$ . Finally, the frozen sample was subjected to lyophilisation at  $-84\text{ }^{\circ}\text{C}$  with a  
121 pressure of  $7\times 10^{-2}$  mbar for 12 h using freeze-dryer (Sub-Zero, USA) to obtain the dried solid.

122

### 123 **2.2 Optimization of GSE loading**

124 GSE-SOLU was prepared using different loadings such as 1 %, 3 %, 5 % and 7 % of the SOLU  
125 to estimate the percentage of GSE in the soluplus matrix and the changes in the particle size,  
126 polydispersity index, zeta potential and loading of GSE-SOLU. The stirring time, sonication  
127 time and aqueous ratio were kept constant.

128

129

130 **2.3 Loading efficiency (LE)**

131 The content of GSE dispersed in SOLU was estimated by membrane filter method. GSE-SOLU  
132 (0.5 ml) was filtered through the membrane (0.22- $\mu\text{m}$ ), whereas the undispersed GSE was  
133 retained. The filtrate containing GSE-SOLU was mixed with methanol and determined the  
134 dispersed GSE content by HPLC (high-performance liquid chromatography) assay method.  
135 The experiments were done three times to ensure optimal loading.

136

137 **2.4 Fourier transform infrared spectroscopy (FT-IR)**

138 The infrared spectrum of the polymer SOLU, GSE and lyophilized GSE-SOLU (FIII)  
139 formulations were analysed using FT-IR spectrometer (Perkin Elmer). The potential  
140 interactions among the GSE and the SOLU are analysed in the solid form with a frequency of  
141 4000-400  $\text{cm}^{-1}$ .

142

143 **2.5 Powder X-ray diffraction**

144 X-ray diffraction (XRD - D8- Bruker, Germany) with the wavelength of 1.5405980 Å using  
145  $\text{Cu-}\alpha_1$  radiation were used to study the diffraction patterns and crystal structures of GSE,  
146 SOLU and GSE-SOLU nanodispersion formulations.

147

148 **2.6 Distribution of particle size and zeta potential measurements**

149 Particle size, zeta potential and poly dispersity index (PDI) of GSE-SOLU were determined by  
150 nano zetasizer (Horiba Instruments, UK). The GSE-SOLU formulations, GSE, SOLU were  
151 dispersed in distilled water for analysis. Cumulative percentage of particle size and PDI were  
152 obtained using the Horiba software. All experiments were repeated three times.

153

154

155

156 **2.7 Morphological analysis**

157 **2.7.1 Atomic force microscopy (AFM) analysis**

158 The experiments were performed using A.P.E.R research nanotechnology instrument (Italy) in  
159 contact mode imaging method. The samples were diluted with deionized water and a drop of  
160 all the samples was placed separately over the silica wafers surface and dried. After drying, the  
161 samples were subjected to AFM analysis.

162

163 **2.7.2 Scanning electron microscopy (SEM) analysis**

164 The morphologies of GSE, SOLU and the GSE-SOLU formulations were obtained by Jeol-  
165 JSM-5300 scanning electron microscope (Tokyo, Japan). The samples were placed on the glass  
166 stump with double-sided adhesive tape and they are gold coated prior to analysis. Different  
167 magnifications of the images were obtained to study the morphology of the formulations.

168

169 **2.7.3 Transmission electron microscopy (TEM) analysis**

170 The morphology of SOLU, GSE, GSE-SOLU solid dispersions was also analysed by  
171 transmission electron microscopy (JEOL Model-JEM2100). The samples were diluted with  
172 deionized water and a drop of all the samples was individually placed on the grid and dried  
173 prior to analysis. Then, the samples were subjected to TEM analysis.

174

175 **2.8 In-vitro release**

176 The *in-vitro* release of GSE from SOLU was evaluated by simulated intestinal fluid (SIF),  
177 water and water-ethanol mixture. The procedure of Wang et al's was followed to prepare the  
178 SIF which consists of trypsin - 10 g/l, NaCl - 9 g/l, pancreatin - 10 g/l and bile salts - 3 g/l and  
179 this solution was adjusted to a pH of 6.8 [22]. The SIF was kept at 37 °C for incubation and  
180 stirred with a magnetic stirrer continuously. The solution (1 ml) was withdrawn at different  
181 time intervals of 1 h for the first 6 h, then every 3 h for the next 6h and every 8 h for 48 h. They

182 were centrifuged at a rotational speed of 14,000 rpm for 5 min and filtered using Millipore  
183 paper (0.45  $\mu\text{m}$ ). Finally, the PCs content in GSE was estimated by Waters HPLC. The mobile  
184 phase used was acetone/water/acetic acid (70/29.5/0.5 v/v/v) and stationary phase was silica  
185 column (5  $\mu\text{m}$ , 250  $\times$  4.6 mm). Standard and sample were injected separately and the  
186 components eluted was detected by spectrometer. The peaks were quantified and evaluated for  
187 the PCs percentage in the GSE.

188

## 189 **2.9 Antibacterial activity**

190 The GSE-SOLU solid dispersion was tested for antimicrobial activity by agar well diffusion  
191 method against pathogenic bacteria *Proteus sp*, *Staphylococcus aureus*, *Escherichia coli* and  
192 *Bacillus sp*. Luria Bertani Agar medium was used to cultivate bacteria. The agar plate surface  
193 is inoculated by spreading a volume of the microbial inoculum over the entire agar surface.  
194 Fresh overnight culture of each strain was swabbed uniformly onto the individuals plates using  
195 sterile cotton swabs. Then, a hole with a diameter of 6 mm is aseptically punched with a sterile  
196 borer and a measured volume of the GSE-SOLU at desired concentration is introduced into the  
197 well. 3 wells were made on each Luria Bertani Agar plates. Then the centrifuged solution 5  $\mu\text{l}$   
198 of streptomycin (standard), pure GSE, GSE-SOLU solid dispersion, were poured into each well  
199 on all plates and incubated for 24 h at 37°C. After incubation the different levels of zonation  
200 formed around the well was measured.

201

## 202 **2.10 Antioxidant Assays**

### 203 **2.10.1 DPPH free radical scavenging assay**

204 The antioxidant potential was studied on DPPH free radical. The stock solution for this assay  
205 was made by mixing 50  $\mu\text{g}$  of the freeze-dried powder in methanol. Various concentrations of  
206 the stock solutions were mixed with 450  $\mu\text{l}$  of Tris-HCl buffer (50 mM-pH 7.4) and free radical  
207 DPPH (0.1 mM) in methanol. The mixture was vigorously shaken and it was kept in the dark



208 for 20 min. After 30 min of incubation, the decrease in the DPPH free radicals was measured  
209 at 517 nm. The scavenging activity of GSE, GSE-SOLU formulations were calculated by the  
210 following formula,

$$\% \text{ Scavenging Activity} = \frac{\text{Absorbance of Control}}{\text{Absorbance of Test Sample}} \times 100$$

### 214 **2.10.2 ABTS scavenging activity**

215 Arnao et al method was used for evaluating the ABTS radical scavenging activity [23]. ABTS  
216 solution (7.4 mM) was added to potassium persulphate solution (2.6 mM) in equal amounts  
217 and the solution was kept for 12 h in the dark at 25 °C. This was referred to as the stock solution.  
218 The stock solution was diluted again by addition of ABTS solution; 1 ml in 50 mL of methanol  
219 and the absorbance was measured by UV spectrophotometer at 734 nm. For each assay, a  
220 freshly prepared ABTS solution was used. ABTS solution and the samples with different  
221 concentrations were mixed together and kept at room temperature in dark for 2 h. Methanol  
222 was used as blank instead of ABTS solution and the samples absorbance were measured at 734  
223 nm. The scavenging activity was calculated by Trolox equivalents (TE) / ml of the  
224 proanthocyanidins.

### 226 **2.10.3 FRAP assay**

227 The ability of the GSE-SOLU formulations, GSE and SOLU to reduce ferrous ions was  
228 estimated by Oyaizu method [24]. Phosphate buffer (0.2 M- pH 6.6) and potassium ferricyanide  
229 (2.5 ml) mixed with various concentrations of formulations (1 % w/v) and kept in incubator for  
230 30 min at 50 °C. After incubation, 10 % w/v trichloroacetic acid (2.5 ml) was mixed to the  
231 above solution and treated as stock solution. 2.5 ml of stock solution was added to 0.1 % w/v

232 ferric chloride (0.5 ml) and distilled water (2.5 ml) and it is allowed to react for 10 min. Then,  
233 the absorbance of the samples was evaluated by a UV-VIS spectrophotometer at 700 nm.

234

#### 235 **2.10.4 Lipid peroxidation inhibition**

236 The inhibitory activity of GSE, SOLU and GSE-SOLU formulations was measured using the  
237 Osawa and Namiki [25] method. Linoleic acid (0.13 ml), 50 mM phosphate buffer (10 ml-pH  
238 7.0) and 99.5 % ethanol (10 ml) were dissolved in different concentrations of sample and the  
239 volume was made up with distilled water to 25 ml. Each mixture was subjected to incubation  
240 for 5 days at 40 °C in dark. Ferric thiocyanate method was used to measure the degree of  
241 oxidation. The incubated mixture (0.1 ml) was added to 20 mM of 0.1 ml ferrous chloride, 30  
242 % of 0.1 ml of ammonium thiocyanate and 75 % ethanol (4.7 ml) solution and incubated for 3  
243 mins. After incubation, the inhibition of peroxide formation was evaluated at 500 nm. The  
244 scavenging activity was calculate by;

$$245 \quad \% \text{ Lipid Peroxide Inhibition} = 1 - \frac{\text{Absorbance of Sample}}{\text{Absorbance of Control}} \times 100$$

246

247

#### 248 **2.11 In-vitro cytotoxicity study**

249 *In-vitro* cytotoxicity of Pure GSE, SOLU and GSE-SOLU nanodispersion were evaluated by  
250 measuring the viability of HCT-116 cells in the presence of different concentrations of  
251 nanodispersion. Cell viability was determined by MTT assay (3-(4, 5-dimethylthiazol-2-yl)-2,  
252 5-diphenyltetrazolium bromide). After plating for about 24 hrs, different amounts of GSE,  
253 SOLU and GSE-SOLU nanodispersion which are suspended in the culture medium were added  
254 in the wells. After incubating at 37°C for 24 hrs, MTT solution (100 µL) were added into each  
255 well and incubated for 3 h. MTT is cleaved by mitochondrial succinate dehydrogenase and  
256 reductase of viable cells which yields a measurable purple product formazan. The production  
257 of formazan is proportional to the viable cell number and inversely proportional to the degree

258 of cytotoxicity. Then each of the prepared sample solution was read on a Lark LIPR-9608  
259 microplate reader at a wavelength of 540 nm. The cytotoxicity and the biocompatibility of the  
260 nanodispersion were stated as % cell viability. It was calculated from the ratio between the  
261 number of cells treated with the nanodispersion and that of control (non-treated cells)[26].  
262

### 263 **3. Results and discussion**

#### 264 **3.1 Optimisation of GSE loading**

265 Several presentations of GSE-SOLU were formulated with different ratios of SOLU loading,  
266 i.e., 1 %, 3 %, 5 % and 7 % of polymer to examine the accurate percentage of GSE in SOLU  
267 matrix. Table 1 shows that initial SOLU loading affected the particle size distribution  
268 significantly ( $p < 0.05$ ). It is clearly shown that an increase in SOLU loading from 1 % to 5 %  
269 resulted in a decrease in the particle size of the formulation. Subsequently, the particle size of  
270 the formulation increased as SOLU loading was further increased to 7 %. The 5 % SOLU  
271 loading produced a highly stable formulation with highest loading efficacy of about  $95.36 \% \pm$   
272  $2.06 \%$  and negative zeta potential ( $-82.1 \pm 1.07$ ). The particle size of the FIII formulation was  
273 found to be the smallest particle size ( $69.90 \pm 2.12$  nm) with PDI of  $0.154 \pm 0.023$ . FIII  
274 formulation showed the highest loading and stability and therefore, it was selected for further  
275 physicochemical analysis.  
276

#### 277 **3.2 Fourier transform infrared (FT-IR) spectroscopy**

278 Fig. 2(a) shows the FTIR spectra of SOLU, GSE and FIII dispersion. SOLU displayed a broad  
279 peak at  $3613 \text{ cm}^{-1}$  which can be attributed to O–H vibrational stretching. The peaks at  $2914$   
280  $\text{cm}^{-1}$ ,  $1737 \text{ cm}^{-1}$  and  $1627 \text{ cm}^{-1}$  are attributed to C–H stretching, C=O and N-H bending  
281 vibration respectively. The ether C–O–C has a characteristic peak at  $1443 \text{ cm}^{-1}$ . GSE show  
282 characteristic bands representing O-H stretching at  $3319 \text{ cm}^{-1}$ , C-C stretching at  $1590 \text{ cm}^{-1}$  and  
283 C-O stretching at  $1094 \text{ cm}^{-1}$ . The position of the carbonyl peak in the dispersion SOLU- GSE

284 (FIII) was shifted to  $1737.93\text{ cm}^{-1}$  and this shifting led to polar-polar interactions. The FIII  
285 formulation, also show a peak broadening from  $3619\text{ cm}^{-1}$  to  $3265\text{ cm}^{-1}$  indicating an  
286 intermolecular hydrogen bonding between GSE and SOLU. The interaction between soluplus  
287 and GSE is hydrogen bonding, which results in the shifting and peak broadening of the  
288 absorption bands at the interacting functional groups on the FT-IR. The observed FT-IR results  
289 are well corroborated with the reports of Dian et al and Bakshi et al [27, 28].

290

### 291 **3.3 X-ray diffraction study**

292 The diffraction pattern in Fig. 2(b) for the neat SOLU and GSE show broad peaks at 20 and  
293 22, indicating their amorphous nature. The addition of SOLU to the GSE completely eliminate  
294 the broad peak, indicating a hydrogen bonding and a  $\pi$ - $\pi$  interactions between GSE and SOLU  
295 molecules. The FIII formulation showed no characteristic peak which indicated that GSE was  
296 completely amorphous. Soluplus has been demonstrated to retard and inhibit the  
297 crystallization, giving amorphous solid dispersions. A similar result has been previously  
298 reported by Shamma et al [29] on carvedilol-SOLU dispersion.

299

### 300 **3.4 AFM Analysis**

301 The surface topography of the prepared GSE-SOLU dispersion was studied with atomic force  
302 microscopy. The pure SOLU exhibited a sheet-like morphology (Fig. 3(a) while GSE is  
303 spherical in shape (Fig. 3(b). As shown in Fig 3(c-f), the GSE-SOLU formulations (FI-FIV)  
304 show particles that are dispersed in the polymer matrix. In the FI formulation, the particle size  
305 is deformed and very large. The GSE-SOLU dispersion in the FII formulation show  
306 agglomeration with less distribution over the polymer surface. The FIII formulation displays  
307 particles with relatively uniform size distribution throughout the polymer matrix. The FIV  
308 formulation micrographs clearly demonstrated a highly crosslinked morphology with increase  
309 aggregates over the polymer matrix. Liu et al reported that the proanthocyanidins-Insulin

310 hybrid nanoparticles showed a controlled morphology with spherically shaped particles. They  
311 also mentioned that medium concentration showed good stability to form uniform sized  
312 particles [30]. The surface roughness data is displayed in Fig. 3 (g-l). The AFM 3D surface  
313 imaging study of GSE-SOLU formulations help us to understand the surface morphology of  
314 GSE-SOLU and their interactions. The AFM images indicates the amorphous nature of GSE  
315 in the SOLU of the dispersions and showed high surface interaction. Bhagel *et al.*, revealed  
316 that SOLU showed uniform distribution and stability of the dispersion. Therefore the results  
317 are similar with the reports of Bhagel et al and Fule et al [31, 32].

318

### 319 **3.5 SEM Analysis**

320 SEM images of GSE and the FIII formulations were used to examine their morphological  
321 changes Fig 4. Fig 4(b) reveals that GSE exists as spherically shaped smooth surfaced particles  
322 and SOLU (Fig 4(a) appears to be thin flat sheet-like in appearance. The FIII formulation  
323 exhibited a homogenous dispersion in which the spherically shaped particles of GSE (Fig 4(c)  
324 & (d)).

325

### 326 **3.6 TEM Analysis**

327 The morphology of the SOLU, GSE, FIII GSE-SOLU dispersions and the selected area  
328 diffraction pattern (SAED) of FIII freeze-dried formulation are shown in Fig 4. From the  
329 micrographs, it is evident that SOLU (Fig 4(e)) has a flat thin sheet-like morphology, GSE (Fig  
330 4(f)) appears to have a spherically shaped structure and in Fig 4(g) it is clear that the spherically  
331 shaped particles of GSE are embedded on the surface of the polymer which has a thin flat sheet-  
332 like morphology. The freeze-dried solid dispersion FIII (Fig 4(g)) show that the spherically  
333 shaped particles of GSE are well distributed in the polymer matrix. The SAED image (Fig 4(h))  
334 show the absence of the diffused rings which confirms the amorphous nature of the freeze-  
335 dried solid dispersion.

### 336 **3.7 *In-vitro* release**

337 The controlled release behaviour of PCs is shown in Fig 5. The release of PCs decreases with  
338 increase in polymer content. The results show that the PCs release at pH 6.8 from SOLU may  
339 be due to the formation of pores after the swelling of the polymer. Dissolution profiles of  
340 formulations FIII show a lower burst effect with 20.00 % dissolved after 2 h and the final  
341 concentration was about 68.05 % after 48 h. Thus, it is evident that the increased polymer ratio  
342 was responsible for the decreased dissolution rate and lower burst effect. The hydrophobic  
343 ability of the polymer was greater than its hydrophilic capability. When SOLU was blended  
344 with PCs, the interaction or affinity between the polymer and SOLU might be enhanced and  
345 thus caused the slower release. The pure GSE from the solution exhibited about 97.33 % release  
346 in 2 h. FIII formulation containing GSE-SOLU suspension displayed a controlled release  
347 behaviour and the release at 48 h was 68.05% [33]. The inset in the Fig 3 shows that about 45-  
348 50 % of GSE was released in 6 h. The amount of proanthocyanidins in ethanol solutions  
349 depends on the percentage of ethanol in the medium. The presence of ethanol in the  
350 gastrointestinal tract didn't cause any alterations in the dissolution but the dissolution profile  
351 was found to be very less compared to SIF. The *in-vitro* release of proanthocyanidins in water  
352 shows a comparable dissolution behaviour as that of SIF. Similar result had been reported in  
353 Lu *et al's* work for the procyanidins release in tea after 6 h [34].

354

### 355 **3.8 Antibacterial activity**

356 The antimicrobial activity of standard (erythromycin), GSE and GSE-SOLU solid dispersion  
357 was tested using the agar well diffusion method (Fig 6A). The zone of inhibition as seen in  
358 Fig 6B showed the range of 3-6 mm for standard, 5-8.5 mm for GSE and 9-13 mm for GSE-  
359 SOLU solid dispersion (FIII). The result of the present investigation highlights the greater  
360 antibacterial potential of the solid dispersion than for the pure GSE and the standard drug. The  
361 higher antimicrobial activity of GSE-SOLU solid dispersion may be because of the amphiphilic

362 nature of SOLU which interacts with the cell membrane of the bacterial cell wall to release the  
363 GSE promptly from the solid dispersion. Nirmala et al studied the antimicrobial activities of  
364 GSE (10 µl) and they found the zone of inhibition in the range of 8-16 mm [35]. In our study  
365 we have obtained similar results by using only 5 µl of the samples and found good antibacterial  
366 activity with a zone of inhibition of 9-13 mm[33].

367

### 368 **3.9 Antioxidant Activity**

#### 369 **3.9.1 DPPH**

370 The electron (hydrogen) donating ability of GSE, SOLU and GSE-SOLU formulations were  
371 measured. The reaction between DPPH and the antioxidants gave an estimation of the  
372 scavenging ability. The DPPH solution was purple in colour and upon addition of the GSE-  
373 SOLU formulations, it became colourless. This discolouration indicates a higher scavenging  
374 capacity via donation of the proanthocyanidins hydrogen to the free radicals. In addition, the  
375 GSE and the GSE-SOLU formulations exhibited an increase in scavenging the free radicals  
376 with an increase in concentration.

377

378 The scavenging activity of different concentrations of GSE and GSE-SOLU formulations are  
379 shown in Fig 7(b). When the concentration of GSE-SOLU formulation (FIII) was increased to  
380 200 µg/ml, it displayed the highest scavenging ability of about 96.09 % when compared with  
381 GSE. The presence of a functional group –OH and a flavonoid moiety in the proanthocyanidins  
382 performs the scavenging activity against the free radicals such as hydroxyl, superoxide, DPPH  
383 and a reduction in the formation of hydrogen peroxide (Fig 7(a)). Moreover, the reason for  
384 higher antioxidant activity could be due to the presence of monomeric, dimeric and oligomeric  
385 proanthocyanidins [36]. Arora et al., also reported that the antioxidant ability can be determined  
386 by the presence of a functional group and the position of proanthocyanidin molecule [37].

387

388 The data presented in Fig 7 were analyzed to evaluate the % inhibition of DPPH of GSE and  
389 GSE-SOLU formulations (FI-FIV). A Calibration curve was created by plotting the  
390 concentrations of GCE and GSE-SOLU formulations against DPPH scavenging activity. The  
391 corresponding  $R^2$  values showed the % antioxidant activity. The activity of pure GSE showed  
392 the  $R^2$  value of 0.95925, FI-0.90647, FII-0.95017, FIII-0.97628 and FIV-0.95132 (Fig 8). From  
393 the  $R^2$  values, it was found that the equimolar concentration of GSE-SOLU formulations and  
394 pure GSE have similar scavenging ability. This confirms the protection of complete functional  
395 moiety of GSE when dispersed with the SOLU matrix.

396

### 397 **3.9.2 ABTS radical scavenging activity**

398 The antioxidant ability of GSE, GSE-SOLU formulations was tested against long shelf life  
399 radical ABTS. They formed an intense coloured solution when ABTS reacted with oxidants  
400 and peroxy radicals. The scavenging activity was measured by the ability of GSE and GSE-  
401 SOLU formulations in decreasing the colour intensity. When they reacted with radical anion  
402 ABTS. This radical scavenging assay could be used to measure both the hydrophobic and  
403 hydrophilic antioxidants because the reagents used in this method acted well in both types of  
404 antioxidants. Table 2 shows the ABTS radical scavenging activity of GSE and GSE-SOLU  
405 formulations. The antioxidant activity of GSE and GSE-SOLU show increased activity as the  
406 concentration increased but the activity varies with the pure GSE and GSE-SOLU  
407 formulations. Hence, both the GSE and GSE-SOLU formulations exhibited a dose-dependent  
408 scavenging activity. In addition, there was no significant difference in the antioxidant activity  
409 when the concentration was increased from 120 to 200  $\mu\text{g/ml}$  ( $p > 0.05$ ). Our results  
410 corroborated well with the work reported by Sofi et al and Selcuk et al [38, 39]. The dose-  
411 dependent activity is due to the presence of hydroxyl groups, number of aromatic rings in the  
412 chemical structure and molecular weight of the molecule [40]. The formulations exhibited a  
413 strong antioxidant activity because the polymer SOLU also acts as an antioxidant along with



414 the GSE. The results suggest that the formulation was found to be a strong ABTS radical  
415 inhibitor when compared with GSE.

416

### 417 **3.9.3 FRAP assay**

418 It was found that the reducing ability of GSE and GSE-SOLU formulations could make them  
419 acts as good antioxidants. In FRAP assay, we measured the reduction of ferric ( $\text{Fe}^{3+}$ ) 2, 4, 6  
420 tripyridyl-5-triazine (TPTZ) to a ferrous ( $\text{Fe}^{2+}$ ) product. During the reduction, the  $\text{Fe}^{2+}$  showed  
421 the formation of Perl's Prussian blue colour. Table 2 shows the reducing capacity of GSE and  
422 GSE-SOLU formulations at different concentrations. The reducing capacity of GSE and GSE-  
423 SOLU formulations increased when the concentration increased. When compare with all the  
424 other formulations, FIII and FIV show the highest reducing power. The highest reducing power  
425 of the FIII and FIV formulations can be attributed to the presence of many hydroxyl groups in  
426 their structure and the polymer (SOLU).

427

### 428 **3.9.4 Linoleic acid emulsion system assay**

429 The quality of food commodities is affected by several factors. Among these, lipid auto-  
430 oxidation is one of the most undesirable factors that can deteriorate the food and food  
431 components. The importance of protecting the food against oxidative damage has prompted the  
432 wider usage of antioxidants from natural origin. Rancidity occurs due to the rapid development  
433 of lipid peroxidation and it is measured as a main mechanism of quality deterioration in lipids.  
434 GSE and GSE-SOLU formulations prevented the lipid peroxidation by means of free radical  
435 scavenging and electron transfer mechanisms. During the processing of lipid foods, these  
436 antioxidants can be added to suppress lipid peroxidation, to improve the stability and quality  
437 of the food product. And also, the lipid peroxidation of the cellular membrane causes  
438 pathological illness which leads to atherosclerosis, inflammation and other diseases. The  
439 reducing property of GSE-SOLU formulation indicates that they can be used as electron donors

440 which reduces lipid peroxidation processes [41]. The main mechanism in this assay is that the  
441 polymer SOLU protects the GSE and slowly releases the electron from the proanthocyanidins  
442 to scavenge the harmful peroxidase radical. This property increases the operational stability  
443 and shielding effect of PEG-PCL-PVA (SOLU) in scavenging peroxidase radical. The  
444 percentage of lipid peroxidase inhibition showed increased activity in the GSE-SOLU  
445 formulations compared with GSE (Table 2). This indicates that SOLU does not only possess  
446 antioxidant activity but also increases the stability of the formulations [42].

447

### 448 **3.10 *In-vitro* cytotoxicity**

449 The GSE used in this study contains only proanthocyanidins and in addition, there are no  
450 reported studies on the controlled release formulation of solid dispersions containing  
451 proanthocyanidins and SOLU. To determine the cytotoxic activities of pure GSE and GSE-  
452 SOLU solid dispersion, studies were performed on human colon cancer cells by MTT assay.  
453 The fabricated system did not exhibit any cytotoxicity to the normal cells during the analysis,  
454 confirming that the SOLU act merely as a suitable vehicle for proanthocyanidins. The SOLU  
455 in a concentration of 200 µg/mL were treated with the cells and subjected for 24 h incubation.  
456 They showed cell viability above 96%, indicating that the synthesized hybrid system were  
457 highly biocompatible with the colon cells. Hence it was concluded that the nanoparticles  
458 themselves did not have any harmful effects on living cells. This clearly revealed their safe  
459 application inside the body during proanthocyanidins delivery (Fig 9).

460

## 461 **4. Conclusions**

462 GSE was successfully dispersed on the soluplus matrix using the freeze-drying method with a  
463 loading efficiency of 95.36 %. The mean diameter of GSE-SOLU dispersion was ~69.90 and  
464 PDI of 0.154. The FT-IR analysis indicates an intermolecular hydrogen bonding between the  
465 GSE and SOLU. The morphological analysis proved that spherically shaped particles of GSE

466 are well distributed in the polymer matrix. In this study, GSE-SOLU formulations were  
467 screened for antioxidant property. *In-vitro* antioxidant assays showed that the functional  
468 property of GSE was protected after dispersion into the polymer matrix. The study also  
469 revealed that GSE and SOLU possess higher hydroxyl group emphasizing its impact in the *in-*  
470 *vitro* anti-oxidative activity assays. Therefore, it can be recommended that the GSE-SOLU be  
471 used as a promising antioxidant compound in the food industry. The results of the present work  
472 denotes that GSE constitutes a good source of PC's and will be useful in the prevention and  
473 treatment of free radical related diseases. In addition, the resultant GSE-SOLU dispersion could  
474 also be used as an antioxidant in many applications such as antidiabetic, anticancer, anti-  
475 inflammatory and in wound healing applications.

476

477 **Acknowledgements:** The authors wish to express their sincere thanks to the DST-Inspire  
478 Fellowship, Department of Science and Technology, New Delhi for their financial support.  
479 This study was also financially supported by Project “Agropreparations of the new generation:  
480 a strategy of construction and realization” (Agreement No 074-02-2018-328) in accordance  
481 with Resolution No 220 of the Government of the Russian Federation of April 9, 2010, “On  
482 measures designed to attract leading scientists to the Russian institutions of higher learning”.

483

#### 484 **Ethical standards**

485 The manuscript does not contain clinical studies.

486

#### 487 **Conflict of interest**

488 The authors declare no conflict of interest.

489

#### 490 **References**

491 [1] Delgado Adámez, J.; Gamero Samino, E.; Valdés Sánchez, E.; González-Gómez, D. In

- 492 Vitro Estimation of the Antibacterial Activity and Antioxidant Capacity of Aqueous  
493 Extracts from Grape-Seeds (*Vitis Vinifera* L.). *Food Control*, **2012**, *24* (1–2), 136–141.  
494 <https://doi.org/10.1016/j.foodcont.2011.09.016>.
- 495 [2] Songsermsakul, P.; Pornphairin, E.; Porasuphatana, S. Comparison of Antioxidant  
496 Activity of Grape Seed Extract and Fruits Containing High  $\beta$ -Carotene, Vitamin C, and  
497 E. *Int. J. Food Prop.*, **2013**, *16* (3), 643–648.  
498 <https://doi.org/10.1080/10942912.2011.561462>.
- 499 [3] Katalinić, V.; Možina, S. S.; Skroza, D.; Generalić, I.; Abramovič, H.; Miloš, M.;  
500 Ljubenković, I.; Piskernik, S.; Pezo, I.; Terpinc, P.; et al. Polyphenolic Profile,  
501 Antioxidant Properties and Antimicrobial Activity of Grape Skin Extracts of 14 *Vitis*  
502 *Vinifera* Varieties Grown in Dalmatia (Croatia). *Food Chem.*, **2010**, *119* (2), 715–723.  
503 <https://doi.org/10.1016/j.foodchem.2009.07.019>.
- 504 [4] Subbaiya, R.; Lavanya, R. S.; Selvapriya, K.; Selvam, M. M. Original Research Article  
505 Green Synthesis of Silver Nanoparticles from *Phyllanthus Amarus* and Their  
506 Antibacterial and Antioxidant Properties. **2014**, *3* (1), 600–606.
- 507 [5] Ma, Q.; Ren, Y.; Wang, L. Investigation of Antioxidant Activity and Release Kinetics  
508 of Curcumin from Tara Gum/ Polyvinyl Alcohol Active Film. *Food Hydrocoll.*, **2017**,  
509 *70*, 286–292. <https://doi.org/10.1016/j.foodhyd.2017.04.018>.
- 510 [6] Nagaich, U.; Gulati, N.; Chauhan, S. Antioxidant and Antibacterial Potential of Silver  
511 Nanoparticles: Biogenic Synthesis Utilizing Apple Extract. *J. Pharm.*, **2016**, *2016*, 1–8.  
512 <https://doi.org/10.1155/2016/7141523>.
- 513 [7] From, A. B.; Hills, K.; Ghats, E.; Tamilnadu, O.; Sathish, S. S.; Vimala, A.; Kanaga, A.;  
514 Murugan, M. Antioxidant and Antimicrobial Studies on Biosynthesized Silver  
515 Nanoparticles Using *Bryum Medianum* Mitt . **2016**, *8* (1), 704–709.
- 516 [8] Mandić, A. I.; Đilas, S. M.; Četković, G. S.; Čanadanović-Brunet, J. M.; Tumbas, V. T.  
517 Polyphenolic Composition and Antioxidant Activities of Grape Seed Extract. *Int. J.*

- 518 *Food Prop.*, **2008**, *11* (4), 713–726. <https://doi.org/10.1080/10942910701584260>.
- 519 [9] Cos, P.; De Bruyne, T.; Hermans, N.; Apers, S.; Berghe, D. Vanden; Vlietinck, a J.  
520 Proanthocyanidins in Health Care: Current and New Trends. *Curr. Med. Chem.*, **2004**,  
521 *11* (10), 1345–1359. <https://doi.org/10.2174/0929867043365288>.
- 522 [10] Santos-Buelga, C.; Scalbert, A. Proanthocyanidins and Tannin like Compounds Nature,  
523 Occurrence, Dietary Intake and Effects on Nutrition and Health. *J. Sci. Food Agric.*,  
524 **2000**, *80* (May), 1094–1117. [https://doi.org/10.1002/\(SICI\)1097-0010\(20000515\)80](https://doi.org/10.1002/(SICI)1097-0010(20000515)80).
- 525 [11] Ou, K.; Gu, L. Absorption and Metabolism of Proanthocyanidins. *J. Funct. Foods*, **2014**,  
526 *7* (1), 43–53. <https://doi.org/10.1016/j.jff.2013.08.004>.
- 527 [12] Antonacci D, B. M. Anticancer Effects of Grape Seed Extract on Human Cancers: A  
528 Review. *J. Carcinog. Mutagen.*, **2014**, *s8* (01), 1–14. [https://doi.org/10.4172/2157-](https://doi.org/10.4172/2157-2518.S8-005)  
529 [2518.S8-005](https://doi.org/10.4172/2157-2518.S8-005).
- 530 [13] Mansouri, E.; Panahi, M.; Ghaffari, M. A.; Ghorbani, A. Effects of Grape Seed  
531 Proanthocyanidin Extract on Oxidative Stress Induced by Diabetes in Rat Kidney. *Iran.*  
532 *Biomed. J.*, **2011**, *15* (3), 100–106.
- 533 [14] Deeban, A.; Anand, K.; Lakshmi, T. In Vitro Anti Arthritic Activity of Grape Seed  
534 Ethanolic Extract. *Int. J. Pharmacogn. Phytochem. Res.*, **2015**, *7* (5), 977–979.
- 535 [15] Wu, C. S. Enhanced Antibacterial Activity, Antioxidant, and in Vitro Biocompatibility  
536 of Modified Polycaprolactone-Based Membranes. *Int. J. Polym. Mater. Polym.*  
537 *Biomater.*, **2016**, *65* (17), 872–880. <https://doi.org/10.1080/00914037.2016.1180605>.
- 538 [16] Fine, A. M. Oligomeric Proanthocyanidin Complexes: Applications Oligomeric  
539 Proanthocyanidins. *Altern. Med. Rev.*, **2000**, *5* (2), 144–151.
- 540 [17] Ali, S. Soluplus® – The Solid Solution Opening New Doors in Solubilization . *BASF*  
541 *Prod. Lit.*, **2012**, 1–8.
- 542 [18] Reintjes, T. 10. Kolliphor™ P Grades (Poloxamers). *Solubility Enhanc. with BASF*  
543 *Pharma Polym. Solubilizer Compend.*, **2011**, 103–111.

- 544 [19] Vasconcelos, T.; Sarmiento, B.; Costa, P. Solid Dispersions as Strategy to Improve Oral  
545 Bioavailability of Poor Water Soluble Drugs. *Drug Discov. Today*, **2007**, *12* (23–24),  
546 1068–1075. <https://doi.org/10.1016/j.drudis.2007.09.005>.
- 547 [20] Zsombor K. Nagy, Attila Balogh, Balazs Vajna, Attila Farkas, Grego Patyi, A. K. and  
548 G. M. Comparison of Electrospun and Extruded Soluplus-Based Solid Dosage Forms of  
549 Improved Dissolution. *J. Pharm. Sci.*, **2012**, *101* (1), 322–332.  
550 <https://doi.org/10.1002/jps>.
- 551 [21] Gibis, M.; Rahn, N.; Weiss, J. Physical and Oxidative Stability of Uncoated and  
552 Chitosan-Coated Liposomes Containing Grape Seed Extract. *Pharmaceutics*, **2013**, *5*  
553 (3), 421–433. <https://doi.org/10.3390/pharmaceutics5030421>.
- 554 [22] Z. Wang, X. Ju, R. He, J. Yuan, R. E. A. Effect of High Pressure Treatment on Rapeseed  
555 Protein Microparticle Properties and Gastrointestinal Release Behavior of the  
556 Encapsulated Peptides,. *Food Res. Int.*, **2015**, *77*, 549–555.
- 557 [23] Arnao, M., Cano, A., & Acosta, M. The Hydrophilic and Lipophilic Contribution to Total  
558 Antioxidant Activity. *Food Chem.*, **2001**, *73* (2), 239–244.
- 559 [24] Oyazu, M. Studies of Product Browning Reaction: Antioxidant Activity of  
560 Productbrowning Reaction from Glucosamine. *Jap. J. Nut*, **1986**, *44*, 315–397.
- 561 [25] Osawa, T.; Namiki, M. Natural Antioxidants Isolated from Eucalyptus Leaf Waxes. *J.*  
562 *Agric. Food Chem.*, **1985**, *33* (5), 777–780.
- 563 [26] Bahuguna, A.; Khan, I.; Bajpai, V. K.; Kang, S. C. MTT Assay to Evaluate the Cytotoxic  
564 Potential of a Drug. *Bangladesh J. Pharmacol.*, **2017**, *12* (2), 115–118.  
565 <https://doi.org/10.3329/bjp.v12i2.30892>.
- 566 [27] Dian, L.; Yu, E.; Chen, X.; Wen, X.; Zhang, Z.; Qin, L.; Wang, Q.; Li, G.; Wu, C.  
567 Enhancing Oral Bioavailability of Quercetin Using Novel Soluplus Polymeric Micelles.  
568 *Nanoscale Res. Lett.*, **2014**, *9* (1), 1–11. <https://doi.org/10.1186/1556-276X-9-684>.
- 569 [28] Bakshi, P.; Sadhukhan, S.; Maiti, S. Design of Modi Fi Ed Xanthan Mini-Matrices for

- 570 Monitoring Oral Discharge of Highly Soluble Soluplus® – Glibenclamide Dispersion.  
571 *Mater. Sci. Eng. C*, **2015**, *54*, 169–175. <https://doi.org/10.1016/j.msec.2015.05.014>.
- 572 [29] Shamma, R. N.; Basha, M. Soluplus®: A Novel Polymeric Solubilizer for Optimization  
573 of Carvedilol Solid Dispersions: Formulation Design and Effect of Method of  
574 Preparation. *Powder Technol.*, **2013**, *237*, 406–414.  
575 <https://doi.org/10.1016/j.powtec.2012.12.038>.
- 576 [30] Liu, R.; Wang, L.-B.; Huang, R.-L.; Su, R.-X.; Qi, W.; Yu, Y.-J.; He, Z.-M. Self-  
577 Assembled Oligomeric Procyanidin–Insulin Hybrid Nanoparticles: A Novel Strategy for  
578 Controllable Insulin Delivery. *Biomater. Sci.*, **2013**, *1* (8), 834.  
579 <https://doi.org/10.1039/c3bm60066a>.
- 580 [31] Baghel, S.; Cathcart, H.; O’Reilly, N. J. Polymeric Amorphous Solid Dispersions: A  
581 Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization,  
582 and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.  
583 *J. Pharm. Sci.*, **2016**, *105* (9), 2527–2544. <https://doi.org/10.1016/j.xphs.2015.10.008>.
- 584 [32] Fule, R.; Amin, P. Development and Evaluation of Lafutidine Solid Dispersion via Hot  
585 Melt Extrusion: Investigating Drug-Polymer Miscibility with Advanced  
586 Characterisation. *Asian J. Pharm. Sci.*, **2014**, *9* (2), 92–106.  
587 <https://doi.org/10.1016/j.ajps.2013.12.004>.
- 588 [33] Rajendran, R.; Volova, T.; Oluwafemi, O. S.; S, R.; Thomas, S.; Kalarikkal, N. Nano  
589 Formulated Proanthocyanidins as an Effective Wound Healing Component. *Mater. Sci.*  
590 *Eng. C*, **2020**, *106* (February 2019), 110056.  
591 <https://doi.org/10.1016/j.msec.2019.110056>.
- 592 [34] Lu, Q.; Li, D. C.; Jiang, J. G. Preparation of a Tea Polyphenol Nanoliposome System  
593 and Its Physicochemical Properties. *J. Agric. Food Chem.*, **2011**, *59* (24), 13004–13011.  
594 <https://doi.org/10.1021/jf203194w>.
- 595 [35] Grace Nirmala, J.; Narendhirakannan, R. T. In Vitro Antioxidant and Antimicrobial

596 Activities of Grapes (*Vitis Vinifera*. L) Seed and Skin Extracts - Muscat Variety. *Int. J.*  
597 *Pharm. Pharm. Sci.*, **2011**, 3 (4), 242–249.

598 [36] Saito, M.; Hosoyama, H.; Ariga, T.; Kataoka, S.; Yamaji, N. Antiulcer Activity of Grape  
599 Seed Extract and Procyanidins. *J. Agric. Food Chem.*, **1998**, 46 (4), 1460–1464.

600 [37] Arora, A.; Nair, M. G.; Strasburg, G. M. Structure–Activity Relationships for  
601 Antioxidant Activities of a Series of Flavonoids in a Liposomal System. *Free Radic.*  
602 *Biol. Med.*, **1998**, 24 (9), 1355–1363.

603 [38] Sofi, F. R.; Raju, C. V.; Lakshisha, I. P.; Singh, R. R. Antioxidant and Antimicrobial  
604 Properties of Grape and Papaya Seed Extracts and Their Application on the Preservation  
605 of Indian Mackerel (*Rastrelliger Kanagurta*) during Ice Storage. *J. Food Sci. Technol.*,  
606 **2016**, 53 (1), 104–117. <https://doi.org/10.1007/s13197-015-1983-0>.

607 [39] Selcuk, A. R.; Demiray, E.; Yilmaz, Y.; Kelimeler, A.; Aktivite, A. Antioxidant Activity  
608 of Grape Seeds Obtained from Molasses ( Pekmez ) and Winery Production. *Akad. Gıda*,  
609 **2011**, 9 (5), 39–43.


610 [40] Spigno, G.; De Faveri, D. M. Antioxidants from Grape Stalks and Marc: Influence of  
611 Extraction Procedure on Yield, Purity and Antioxidant Power of the Extracts. *J. Food*  
612 *Eng.*, **2007**, 78 (3), 793–801. <https://doi.org/10.1016/j.jfoodeng.2005.11.020>.

613 [41] Jayaprakasha, G. K.; Singh, R. P.; Sakariah, K. K. Antioxidant Activity of Grape Seed  
614 (*Vitis Vinifera*) Extracts on Peroxidation Models in Vitro. *Food Chem.*, **2001**, 73 (3),  
615 285–290. [https://doi.org/10.1016/S0308-8146\(00\)00298-3](https://doi.org/10.1016/S0308-8146(00)00298-3).

616 [42] Piao, J.; Lee, J. Y.; Bae, J. W.; Ma, C. J.; Ko, H. J.; Kim, D. D.; Kang, W. S.; Cho, H.  
617 *J. Angelica Gigas Nakai* and Soluplus-Based Solid Formulations Prepared by Hot-  
618 Melting Extrusion: Oral Absorption Enhancing and Memory Ameliorating Effects.  
619 *PLoS One*, **2015**, 10 (4), 1–19. <https://doi.org/10.1371/journal.pone.0124447>.

620  
621






622  
623  
624  
625  
626  
627  
628  
629


630 **Graphical Abstract: Process of GSE-SOLU dispersion and its antioxidant activity (a)**  
 631 **Grape seed extract (b) Soluplus (c) Mixing of GSE and SOLU using magnetic stirrer (d)**  
 632 **Probe sonication (e) Lyophilisation (f) Lyophilised powder (GSE-SOLU dispersions) (g)**  
 633 **FIII formulation for further studies (h) Morphology showing uniform dispersion of GSE**  
 634 **in the SOLU matrix (i) Antioxidant activity (j) DPPH calibration curve**

635  
636  
637  
638  
639  
640  
641  
642  
643  
644




643 **Fig. 1 Mechanism of antioxidant system**

645



646 **Fig 2 (A) FTIR spectra of SOLU, GSE and FIII dispersion and (B) X-ray diffractograms**  
647 **of SOLU, GSE and FIII dispersion**

648




649 **Fig. 3 AFM images of (a) SOLU, (b) GSE, (c) FI, (d) FII, (e) FIII, (f) FIV GSE-SOLU**  
650 **dispersions, 3D AFM images of (g) SOLU, (h) GSE, (i) FI, (j) FII, (k) FIII, (l) FIV GSE-**  
651 **SOLU dispersions**

653

654

655


656



657


658 **Fig. 4 SEM images of (a) SOLU, (b) GSE and (c) & (d) GSE-SOLU (FIII) dispersion and**  
 659 **TEM images of (e) SOLU (0.5 μm), (f) GSE (0.5 μm), (g) GSE-SOLU (FIII) dispersion**  
 660 **(100 nm) and (h) SAED pattern of GSE-SOLU dispersion**

661




662

663 **Fig 5 In-vitro release of GSE and FIII formulation in (a) SIF and (b) Ethanol (20 % &**  
 664 **40 %), Water**




665 Fig 6: (A) Photographs showing the agar well diffusion method of standard (A), GSE (B)  
 666 and GSE-SOLU (FIII) solid dispersion (C), (B) Antibacterial Activity of standard, GSE  
 667 and GSE-SOLU (FIII) solid dispersion against *E. coli*, *S. aureus*, *Bacillus sp* and *Proteus*  
 668 *sp.*

669  
 670




671  
 672 Fig. 7 (a) Molecular representation of antioxidant mechanism of DPPH, (b) Antioxidant  
 673 activity of GSE and formulations FI, FII, FIII & FIV at different concentrations  
 674



675

676 **Fig. 8 DPPH calibration curve of GSE and its formulations. This was obtained by plotting**  
 677 **various amounts of GSE (a), FI (b), FII (c), FIII (d) & FIV (e) formulations (µg/ml) vs. %**  
 678 **inhibition of DPPH**

679



680

681 **Fig. 9 Cell viability upon incubation with SOLU, PCs and PCs-SOLU for 24 h as**  
 682 **determined by MTT assay.**

683

684

685

686

687

688

689

**Table 1 Effects of GSE loading on Size, PDI, ZP and LE**

Formulations	SOLU loading (%)	Size (nm)	PDI	ZP (mV)	LE (%)
FI	1	377.9 ± 3.78	0.184 ± 0.024	-46.8 ± 1.04	87.16 ± 2.04
FII	3	275.5 ± 1.54	1.761 ± 0.042	-48.4 ± 1.24	92.58 ± 2.45
FIII	5	69.90 ± 2.12	0.154 ± 0.023	-82.1 ± 1.07	95.36 ± 2.06
FIV	7	75.80 ± 2.17	0.410 ± 0.031	-43.3 ± 1.00	80.41 ± 3.74

690

**PDI-Poly dispersity index; ZP-Zeta potential; LE-Loading efficiency**

691

692

**Table 2 Antioxidant activity of GSE and GSE-SOLU Formulations**

<b>ABTS radical scavenging</b>					
µg/ml	GSE	FI	FII	FIII	FIV
30	20.54 ± 1.27	21.14 ± 2.40	19.65 ± 1.65	24.25 ± 1.64	22.38 ± 2.31
50	26.59 ± 2.40	25.21 ± 2.80	24.89 ± 1.89	32.15 ± 1.89	28.57 ± 3.21
80	310.00 ± 2.09	307.14 ± 2.45	302.78 ± 1.64	312.67 ± 2.64	311.44 ± 3.14
100	587.32 ± 2.54	579.14 ± 1.58	565.55 ± 2.58	590.28 ± 2.14	594.32 ± 2.98
120	597.34 ± 2.92	584.47 ± 1.98	576.32 ± 2.34	600.47 ± 1.67	599.68 ± 2.64
150	610.21 ± 2.45	592.31 ± 2.38	586.34 ± 1.98	617.24 ± 2.49	615.87 ± 2.70
180	612.84 ± 1.98	607.47 ± 2.84	586.34 ± 2.35	619.58 ± 1.37	618.47 ± 2.45
200	617.53 ± 1.68	611.56 ± 2.31	586.34 ± 2.86	625.34 ± 2.44	626.42 ± 2.31
<b>Ferric reducing antioxidant power</b>					
µg/ml	GSE	FI	FII	FIII	FIV
50	0.25 ± 0.84	0.18 ± 0.82	0.2 ± 1.15	0.28 ± 1.11	0.27 ± 0.89
100	0.38 ± 1.2	0.24 ± 1.00	0.29 ± 1.65	0.40 ± 1.45	0.38 ± 1.09
150	0.57 ± 1.1	0.45 ± 1.45	0.49 ± 1.42	0.58 ± 1.21	0.58 ± 1.16
180	0.75 ± 1.4	0.64 ± 1.20	0.68 ± 1.87	0.78 ± 1.01	0.78 ± 1.54
200	0.88 ± 1.1	0.75 ± 1.70	0.84 ± 1.24	0.90 ± 0.98	0.87 ± 1.24
<b>Lipid peroxidation inhibition</b>					
µg/ml	GSE	FI	FII	FIII	FIV
100	47.45 ± 0.85	67.69 ± 0.87	70.00 ± 1.01	72.04 ± 1.06	73.00 ± 1.05
200	52.18 ± 0.56	74.22 ± 1.24	75.24 ± 1.58	78.41 ± 0.98	76.87 ± 1.31
500	66.14 ± 1.20	81.27 ± 1.14	83.21 ± 1.07	86.58 ± 1.21	87.24 ± 1.05

693

694

695

696